Background: Patients with severe asthma appear relatively corticosteroid resistant.
eosinophilic inflammation was associated with the physiological response to corticosteroids, confirming the importance of measuring eosinophilic inflammation to guide corticosteroid use.
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| INTRODUCTION
Asthma is a common condition characterized by variable airflow obstruction in association with airway inflammation which is commonly, although not invariably eosinophilic. 1 For the majority of people with asthma, their disease can be controlled with modest doses of inhaled corticosteroids (ICS) and bronchodilators. However, in about 5% of people, disease control is more difficult to achieve. The most common cause of poor control of asthma is suboptimal adherence to treatment, especially with ICS. 2, 3 Other reasons for symptoms despite large amounts of treatment include treatment unresponsive lung damage (usually fixed airflow obstruction or bronchiectasis), symptoms caused by alternative diagnoses, in particular various patterns of dysfunctional breathing, and comorbidities such as obesity, obstructive sleep apnoea and psychological morbidity. 4 The complexity of difficult to control asthma means that precise definitions of what constitutes severe asthma are elusive. 5 Most definitions, however, are based on the pragmatic approach of patients who are still symptomatic despite high dose ICS and bronchodilators. 6 A treatmentbased definition has its drawbacks as it is influenced by the healthcare system, access to treatment and the prejudices and expertise of the responsible physician. It is also influenced by symptoms to a greater extent than other components of the disease such as the degree of lung damage, the severity of airway inflammation or the risk of severe exacerbations. The term refractory asthma has been used to encompass some of these other parameters and to exclude patients with difficult to control asthma for reasons other than physiologically severe disease. 6, 7 Because, by definition, patients with refractory (severe), asthma are not controlled on high dose steroids these patients are considered relatively corticosteroid resistant.
The concept of corticosteroid resistance in asthma has a long pedigree having been first described in the context of patients who continued to have variable airflow obstruction despite treatment with 2 weeks of oral corticosteroids. 8, 9 This was associated with evidence of in vitro corticosteroid resistance in monocytes. 9 Following this initial report, there have been a large number of studies suggesting various mechanisms for corticosteroid resistance in asthma.
These include defects in T cell responses, abnormal functioning of the glucocorticoid receptor and abnormalities in chromatin remodelling. [10] [11] [12] However, the concept of a corticosteroid resistant phenotype remains controversial, in part because most studies have not linked corticosteroid responsiveness to eosinophilic inflammation which, measured either directly by sputum or blood eosinophils or indirectly by exhaled nitric oxide or nitrosylated bromide, is currently the best biomarker of corticosteroid responsiveness. [13] [14] [15] Airway hyper-responsiveness (AHR) associated with mast cell infiltration of the airway smooth muscle (ASM), which underlies variable airflow obstruction is not a corticosteroid responsive process in the absence of active eosinophilic inflammation. [15] [16] [17] Thus, the defining clinical hallmark of "corticosteroid resistance" (variable airflow obstruction which does not improve with systemic corticosteroids) may be due to an intrinsic abnormality in ASM physiology rather than a defect in the anti-inflammatory corticosteroid signalling pathway.
Our hypothesis is that the majority of patients with severe asthma who appear corticosteroid resistant do not respond (assuming they are taking them as prescribed), because they do not have a steroid responsive disease process, rather than because there is an inherent molecular or cellular defect in the corticosteroid signalling pathway. In order to test this hypothesis, we undertook two studies, which had followed common protocols, to determine the extent to which the immunopathology of severe asthma in comparison with mild/moderate asthma changed in response to 2 weeks of high dose oral prednisolone steroids and how such changes related to lung function.
| METHODS

| Subjects
The study population comprised male and female subjects aged 18-65 years. Subjects in the healthy group were non-smokers, in good health and did not have asthma. Subjects in the asthma groups had a physician's diagnosis of asthma and had demonstrated >12% reversibility in FEV 1 or a methacholine Pc20 of <8 mg/mL, with exclusion of other significant pulmonary disease.
Exclusion criteria included evidence of recent infection that could preclude participation in the corticosteroid trial; history of abnormal bruising or bleeding; concomitant medications such as aspirin, atenolol or metoprolol; and subjects who had changed asthma medication or had an asthma exacerbation within the previous month. All subjects gave written informed consent. This study was approved by local ethics review committees and conducted in accordance with 
| Study design
This was an open-label, parallel-group study in healthy subjects and subjects with asthma (Clintrials.gov NCT00331058 and NCT00327197). The analysis population was drawn from two studies which with respect to the data presented here had essentially Healthy subjects attended a screening visit and underwent baseline assessments within 14 days of undergoing a bronchoscopy.
They returned for follow-up 7-14 days following bronchoscopy and did not receive prednisolone.
| Sample Collection and Analysis
Bronchial biopsies, BAL fluid and sputum were collected before and after prednisolone treatment and subjected to histopathology on bronchial biopsies and cytospins on sputum and BAL cells as previously described. 15 Twenty-nine biomarkers were analysed in the serum using a variety of assays as described (Table S3 ). Limits of quantification were determined for each analyte/assay to ensure reliable data were being obtained. There were low numbers of subjects in groups for sputum cell counts due to lost samples resulting from application of quality control parameters. The sputum sample was considered good if there were at least 200 non-squamous cells, and there were no more than 40% of squamous cells and at least 50% of the sample was viable. Some of the baseline immunohistochemistry data from the Leicester cohort has been previously reported.
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Blood samples for biomarkers were collected at screening, Day 1
and Day 14 from subjects with asthma and at screening and baseline for the healthy group. Pulmonary function assessments were conducted at the follow-up visit for asthma groups and at baseline for the healthy group. For subjects with asthma, PEFR was conducted during run-in period, day 1, day 1, day 13, day 14 and at follow-up and screening for the healthy subjects. Exhaled NO assessments were performed at screening, Day 1, and Day 13 (exhaled NO assessments were performed at screening for healthy subjects).
| Statistical analysis
Analyses were performed testing differences prior to treatment between the asthma severity groups and change in response posttreatment across the asthma groups for all the key variables. If the end-point of interest had a screening and a baseline record, the average was taken as the pre-treatment measure.
The baseline analysis used analysis of variance with the pretreatment value as the response and study ID and cohort as explana- 3 | RESULTS
| Baseline findings
Both the mild/moderate and severe asthma groups had a significantly lower post-bronchodilator FEV 1 than healthy subjects, and the severe group had a significantly lower FEV 1 than the mild/moderate group. Subjects in both asthma groups had a significantly lower methacholine Pc20 than healthy controls with no difference between the asthma groups ( Table 1) . There was a significant increase in the basement membrane thickness in the severe group (15.1 lm) compared to healthy controls (11.8 lm). This represents a mean increase of 3.3 lm, with a 95% confidence interval of (1.06, 5.50) and P=.0045. There was no difference between the mild/moderate group and the healthy controls with a mean value of 10.9 lm in the mild/moderate group.
There was a consistent pattern of increased eosinophilic inflammation in the severe group compared to the healthy subjects. Eosinophil counts/mm 2 were almost 3 times greater in the bronchial submucosa for severe asthmatics compared to healthy subjects (10.78, n=38 for severe asthma; vs 3.68, n=15 for healthy subjects).
Blood eosinophil counts were also more than double, and sputum counts were over four times higher in the severe asthmatic group compared to healthy subjects. Even though cell counts were low within the BAL, there was still an elevated response in the severe group with percentage counts being over five times higher. This strong effect was also evident in the mild/moderate group with subjects showing a consistently higher level of eosinophils with significance in all compartments except for the submucosa (Table 2) .
Although the eosinophilic inflammation was generally more marked in the severe group compared to the mild/moderate group, these differences were not significant. 
| Effect of oral corticosteroids
As shown in Table 3 , there were small increases in post-bronchodilator FEV 1 , % predicted FEV 1 , FVC and PEFR for the mild/moderate and severe groups which showed a consistently significant improvement for the severe group. The severe group (n=46) showed an increase in % predicted FEV 1 from 73.9 pre-treatment to 77.6 posttreatment (increase of 3.7) and the mild/moderate (n=23) group from 87.8 to 89.9 (increase of 2.1). There were minor nonsignificant improvements in Pc20 in both asthma groups with the severe group Results based on ANOVA with post hoc pairwise comparisons between cohort groups. *Significant at the 5% level.
increasing from a baseline value of 0.95-1.41 mg/mL (increase of 48.3%) and the mild/moderate group showing a smaller increase from a baseline of 1.45-1.99 mg/mL (increase of 37%)
As shown in Table 4 , there was a significant fall in the concentration of exhaled nitric oxide for both asthma groups with an average decrease of 34%. There was a highly significant reduction post-corticosteroid in the number of eosinophils in the blood, and the percentage in the sputum and BAL with reductions in the severe group of 75%, 78% and 72%, respectively, and in the mild/ moderate group of 75%, 65% and 64%, respectively. Of the 68 subjects with severe or mild/ moderate asthma, 60 (88%) of them showed a decrease in the number of eosinophils post-treatment. There was also a statistically significant reduction in the number of eosinophils in the bronchial submucosa with a 71% reduction in the mild/ moderate group and a 50% reduction in the severe group. There was a statistically significant increase in neutrophils for the severe group in the peripheral blood, sputum and BAL fluid. The mild/moderate group only showed a significant increase in peripheral blood neutrophils.
The relationship between the change in FEV 1 in response to corticosteroid and baseline measurements from sputum, blood, BAL and submucosa was assessed. Correlation plots of pulmonary function responses with eosinophil responses in blood, BAL and sputum are shown in Figure S1 with the correlation coefficients presented in Table S2 . The severe subjects show a much stronger correlation of baseline eosinophils with change in FEV 1 than the mild/ moderate and severe subjects combined. When assessing the severe subjects alone, the correlation coefficients for blood, sputum and BAL were , also showed significant decreases of 31% and 30%, respectively, in both asthma groups.
There was a smaller but significant decrease of 17% in CCL-13
(MCP-4) in both asthma groups after prednisolone treatment, compared with baseline ( CI of increase: confidence interval of difference (difference: post-prednisolone-pre-prednisolone);CI of ratio: confidence interval of ratio (ratio: post-prednisolone over pre-prednisolone);N: number of subjects with both pre-and post-measures; *Significant at the 5% level.
a Results based on mixed-model ANOVA.
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| 895 a more stringent P-value of P<.002 should be used as a guide for assessing significance.
| Safety
During the treatment period, 24 (21%) subjects reported AEs (Table S3 ).
| DISCUSSION
The two main aims of this study were firstly to determine whether there were inflammatory features in the asthmatic airway which would predict the physiological and immunological response to oral corticosteroids and secondly whether we could document lack of corticosteroid responsiveness in severe asthma compared to mildto-moderate asthma. We found that the only predictor of an improvement in FEV 1 in response to corticosteroids was the baseline eosinophil count. We also found that there were very similar responses to systemic corticosteroids between the mild/moderate and severe groups across a range of measures providing no evidence CI of ratio: confidence interval of ratio (ratio: post-prednisolone over pre-prednisolone); N: number of subjects with both pre-and post-measures; NO: nitric oxide; BAL: bronchoalveolar lavage. *Significant at the 5% level.
to support the concept of corticosteroid resistance as a general feature of severe asthma.
We identified a number of significant differences at baseline between the severe asthmatics and healthy controls including a reduced FEV 1 and methacholine Pc20 as well as increased epithelial basement membrane thickening and the presence of eosinophilic inflammation. These differences were also seen between mild/moderate asthma and healthy controls, but the eosinophilic inflammation was less marked. There were relatively few differences between the severe and mild/moderate groups in terms of baseline physiology, inflammatory markers, structural and cellular changes in the bronchial mucosa and serum mediators with only a lower FEV 1 and an increased basement thickness (consistent with a greater degree of eosinophilic inflammation), reaching significance.
We demonstrated in this study that essentially all the subjects with asthma responded to high dose oral corticosteroids as evi- investigated the response to 2 weeks of oral prednisolone in a large group of severe and mild-to-moderate asthmatics in a double blind placebo-controlled design. 25 They did not undertake bronchoscopy relying on sputum and exhaled nitric oxide (FeNO), as measures of airway inflammation. As in this study, they found that improvements in FEV 1 were related to sputum and blood eosinophils with a sputum count of >3% and a FeNO >45 ppb providing the best sensitivity.
Together these studies are consistent with a model, we proposed a number of years ago in which the primary site of action of corticosteroids in asthma is suppression of eosinophilic airway inflammation. 26 In this study, all the patients in the severe group were on large doses of ICS and in some cases on oral steroids, yet despite this some still had a significant airway eosinophilia which was corticosteroid responsive. A possible explanation is suboptimal compliance with inhaled and oral corticosteroids which is very common in asthma and the most frequent reason for asthma being difficult to control. 3, 27 Another possibility is that there was a greater intensity of eosinophilic inflammation requiring higher doses of steroids to control, although one would expect that the steroid receptors would be maximally occupied by the high doses of potent topical steroids these patients were prescribed. A third explanation is that oral steroids were working at a location different from the ICS, either in the periphery of the lung or another organ such as the bone marrow which is somehow driving the inflammatory process.
Corticosteroids increased the numbers of neutrophils present in the airway and blood, an effect that was more marked in the airways, but not the blood of the severe asthma group for reasons that are not clear. The differences between the mild/moderate and severe groups were modest and not significant but it does suggest an increased sensitivity to the neutrophilic effects of corticosteroids in severe asthma and it is possible therefore that "neutrophilic"
patterns of airway inflammation in some asthmatics is due to a treatment effect rather than the underlying disease process.
A limitation of this study is that it was not placebo controlled.
While the staff measuring the inflammatory markers were blinded to the clinical and physiological changes, we cannot exclude the possibility that some of the changes observed after oral corticosteroids were due to fluctuations in the disease process independent of the corticosteroids themselves (eg because of regression to the mean).
Against this was the very consistent reduction in the blood eosinophil count across all the compartments measured and the requirement for subjects to be recruited during a stable period of disease activity, outside any period of exacerbation. Another weakness is the lack of any quality of life measures. The two studies used different questionnaires for symptom response and in any case the open nature of the study limits the robustness of changes in patient reported outcomes.
We pooled the results from two studies which had followed common protocols. The US study contained two independent centres and the UK one independent centre. We did not find any con- 
